Table 1. Clinical characteristics of the study participants at baseline.

n	86
Sex (male/female)	65/21
Age (years)	58.5 ± 11.1
BMI (kg/m2)	29.3 ± 4.1
HbA1c (%)	7.3 ± 0.8
C-peptide (ng/mL)	2.4 ± 1.3
T-CHO (mg/dL)	192.6 ± 41.0
HDL-C (mg/dL)	50.1 ± 10.0
TG (mg/dL)	183.8 ± 274.5
eGFR (mL/min/1.73m2)	77.7 ± 20.7
Hs-CRP (ng/mL)	2,157.3 ± 4,530.9
IL-6 (pg/mL)	2.5 ± 1.7
LBP (μg/mL)	6.0 ± 3.5
Medication for diabetes
No medication	9 (10.5)
Insulin only or with oral therapy	28 (32.6)
Oral therapy only
SU	8 (9.3)
Metformin	55 (64.0)
Thiazolidine	12 (14.0)
DPP-4 inhibitor	42 (48.8)
Glinide	6 (7.0)
SGLT2 inhibitor	42 (48.8)
GLP-1 receptor agonist	10 (11.6)

Data are expressed as mean ± SD.

Numbers in parentheses are percentages (%).

BMI: Body mass index; T-CHO: Total cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; eGFR: estimated glomerular filtration rate; Hs-CRP: high-sensitivity C-reactive protein; IL-6: interleukin-6; LBP: lipopolysaccharide-binding protein; SU: sulfonylurea; DPP-4: dipeptidyl peptidase-4; SGLT2: sodium-dependent glucose cotransporter-2; GLP-1: glucagon-like peptide-1.